Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388155 | 1.00 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL17025745 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6860387 | 0.87 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL16922129 | 0.86 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL29388191 | 0.86 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL17025839 | 0.86 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL18878374 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL29989048 | 0.83 | CNR2 (1.00) | CNR1CNR2 | |
| Iodide SCHEMBL17025820 | 0.83 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL10093017 | 0.81 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024018420-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-4255416-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS COMPRISING CBD OR THC FOR THE TREATMENT OF CANCER | Pike Therapeutics Inc. (CA) | 2023-10-11 | — | — | EP | disclosed |
| EP-4196113-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pike Therapeutics, Inc. (CA) | 2023-06-21 | — | — | EP | disclosed |
| EP-4175629-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Pike Therapeutics, Inc. (CA) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| EP-4110325-A1 | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022118303-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS COMPRISING CBD OR THC FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS, INC. (CA) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022003623-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PIKE THERAPEUTICS, INC. (CA) | 2022-01-06 | — | — | WO | disclosed |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9656981-B2 | Peripherally-acting cannabinoid receptor agonists for chronic pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656981-B2 | Peripherally-acting cannabinoid receptor agonists for chronic pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656981-B2 | Peripherally-acting cannabinoid receptor agonists for chronic pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| EP-0860168-B1 | Use of central cannbinoid receptor CB1 agonists | BAYER HEALTHCARE AG (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239859-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885 |
| US-20170240521-A1 | PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.